Search Results

The T-Tek Thrombin Time Reagent contains a lyophilized thrombin reagent, for use in the quantitative determination of thrombin time in citrated plasma. The thrombin time test is a one-stage quantitative test performed on diluted plasma samples in the general patient population. The thrombin time test is used to detect disorders of fibrinogen. The T-Tek, Thrombin Time Reagent should only be used in an appropriate clinical laboratory by qualified laboratory professionals.

The T-Tek Thrombin Time Reagent contains a lyophilized thrombin reagent, for use in the quantitative determination of thrombin time in citrated human plasma. The thrombin time test is a one-stage quantitative clotting test performed on citrated plasma samples in the general patient population. The thrombin time test is used to detect disorders of fibrinogen. The T-Tek, Thrombin Time Reagent should only be used in an appropriate clinical laboratory by qualified laboratory professionals. The test may be performed manually, or using semi-automated and automated coagulation analyzers.

Here's an analysis of the acceptance criteria and study proving device performance for the R2 Diagnostics T-Tek, based on the provided 510(k) premarket notification:

Note: This submission is for a medical reagent (thrombin time test) which typically focuses on chemical and functional equivalence to a predicate device, rather than the complex clinical performance metrics often seen with imaging AI devices. Therefore, some of the requested categories (e.g., MRMC studies, ground truth for training) are not directly applicable or explicitly detailed in this type of submission.

Acceptance Criteria and Reported Device Performance

Ask a specific question about this device

Sigma Diagnostics ACCUCLOT™ Thrombin Time Reagent (A8713/A4589) is a device intended to measure fibrinogen concentration and to detect fibrin or fibrinogen split products for the evaluation of bleeding disorders.

Sigma Diagnostics' ACCUCLOT™ Thrombin Time Reagent is intended for use as a screening procedure to detect functional fibrinogen and thrombin inhibitors such as heparin, in citrated plasma. The ACCUCLOT™ Thrombin Time Reagent provides thrombin for fibrinogen hydrolysis and is able to detect normal fibrinogen function even in the presence of severe coagulation abnormalities such as hemophilia (Factor VIII or Factor IX deficiency) or a decrease in factor levels associated with vitamin K deficiency.

The provided text describes the safety and effectiveness of the Sigma Diagnostics' ACCUCLOT™ Thrombin Time Reagent, primarily by demonstrating its substantial equivalence to a legally marketed predicate device, Organon's Thromboquik™ Thrombin Time Reagent.

1. Table of Acceptance Criteria and Reported Device Performance:

Study Proving Acceptance Criteria:

The study proving the device meets the acceptance criteria is a substantial equivalence study comparing the Sigma Diagnostics' ACCUCLOT™ Thrombin Time Reagent to Organon's Thromboquik™ Thrombin Time Reagent (the predicate device).

2. Sample Sizes Used for the Test Set and Data Provenance:

• Correlation Study:
  • AMAX Optical & AMAX Mechanical: N = 101 plasma samples (normal and abnormal)
  • KC4a: N = 49 plasma samples (normal and abnormal)
• Precision Study: Normal and abnormal control plasmas were used, but the specific number of samples or replicates is not explicitly stated, only that the "within run CV" and "total precision" were measured.
• Heparin/Fibrinogen Sensitivity: The text states the reagent's sensitivity but does not provide specific sample sizes for these evaluations.
• Data Provenance: The document does not specify the country of origin of the data. The study appears to be retrospective in the sense that existing plasma samples (normal and abnormal) were used to compare the new device against the predicate.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications:

Not applicable. This study does not involve expert interpretation of results to establish ground truth in the way medical imaging or clinical diagnostics typically would. The "ground truth" for the correlation study is the result obtained from the legally marketed predicate device (Organon's Thromboquik™). For precision, it's the expected value of the control plasmas.

4. Adjudication Method for the Test Set:

Not applicable. This is a quantitative comparison against a predicate device, not an interpretation task requiring adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done:

No, an MRMC comparative effectiveness study was not done. This study focuses on the analytical performance of the new reagent compared to a predicate, not on human reader performance with or without AI assistance.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done:

Yes, the studies described are essentially "standalone" in nature, comparing the performance of the ACCUCLOT™ reagent (the "algorithm" or test method) directly against the predicate Thromboquik™ reagent. There is no human-in-the-loop component described for interpreting the results beyond standard laboratory technician procedures.

7. The Type of Ground Truth Used:

The primary "ground truth" used for substantial equivalence is the results obtained from the legally marketed predicate device (Organon's Thromboquik™ Thrombin Time Reagent). For the precision studies, the ground truth would be the known values of the normal and abnormal control plasmas.

8. The Sample Size for the Training Set:

Not applicable. This study does not describe a machine learning model with a separate training set. The "training" in this context refers to the development and optimization of the reagent itself, not an algorithm.

9. How the Ground Truth for the Training Set Was Established:

Not applicable, as there's no machine learning training set described. The "ground truth" for the development of the reagent would stem from established scientific principles of coagulation testing and chemical reactions.

Ask a specific question about this device

The BC Thrombin Reagent is intended for the determination of the thrombin time in human plasma. The determination of thrombin time is important in:

• The monitoring of heparin therapy.
• The monitoring of fibrinolysis therapy.
• The screening of disorders of fibrin formation.
• The differentiating between a heparin-induced prolongation of the thrombin time and fibrin formation disorders.

The BC Thrombin Reagent consists of lyophilized bovine thrombin and bovine albumin, and buffer solution (HEPES).

The provided document is a 510(k) summary for the BC Thrombin Reagent. This document focuses on demonstrating substantial equivalence to a predicate device rather than comprehensive acceptance criteria and a standalone study for novel device performance. However, I can extract the relevant information from the "Comparative Analysis" and "Precision" sections to address your request as much as possible within the context of this submission.

Here's an analysis based on the provided text:

1. Table of acceptance criteria and the reported device performance

Ask a specific question about this device